10x Genomics Reveals Early Third Quarter 2024 Financials
10x Genomics, Inc. (NASDAQ: TXG), a leader in single cell and spatial biology innovations, has shared preliminary results for its third quarter of 2024. These results reflect the company's ongoing commitment to transforming the landscape of life sciences, particularly amidst shifting market dynamics.
Revenue Insights for the Third Quarter
According to the announcement, the revenue for the third quarter is estimated to be around $151.7 million. This figure marks a slight decrease of approximately 1% compared to the same timeframe last year. The company is actively analyzing various aspects of its financial performance, aiming for clear insights into revenue streams.
Breakdown of Revenue Sources
Delving deeper, the revenue experienced varied shifts across different sources. Here’s a quick overview of the expected revenue by source:
- Instruments Revenue: Estimated at $19.1 million, reflecting a significant decrease of 46% compared to the previous year's third quarter. This consists of about $7.6 million from Chromium instruments and $11.4 million from Spatial instruments.
- Consumables Revenue: Showcased a positive trajectory with around $126.2 million, indicating a growth of 10% over the previous year. This included around $96.5 million from Chromosomes and $29.7 million from Spatial consumables.
- Services Revenue: Estimated at $6.4 million, exhibiting a strong growth rate of 48% year-over-year.
Geographic Revenue Distribution
The report also highlighted revenue distribution by geography:
- Americas: Revenue expected to be about $87.8 million, an 11% decline compared to last year's figures.
- EMEA: Anticipated revenue of approximately $37.9 million, showing an 18% increase from the same period last year.
- APAC: Estimated revenue of $26.0 million, displaying a 15% increase year-over-year.
Cash Reserves and Future Outlook
10x Genomics reported cash and cash equivalents totaling approximately $398 million. This robust cash reserve puts the company in a favorable position to navigate the ongoing challenges and invest in future growth opportunities.
Comments from Leadership
In light of these results, CEO Serge Saxonov remarked, "While our revenue did not meet expectations this quarter, we are undergoing significant changes in our commercial approaches and how we engage customers. Although the transition has been more disruptive than expected, particularly in the Americas, we remain positive about the future opportunities. We believe that our strategies will eventually enhance customer engagement and broaden the access to our pioneering technologies."
Adjustment of Preliminary Results
The preliminary financials disclosed are still subject to adjustment as 10x Genomics finalizes its third quarter statements. It is vital to understand that the results can change as more data becomes available, especially as they conclude their customary reviews for accuracy.
2024 Financial Guidance and Upcoming Events
Investors and stakeholders can look forward to more comprehensive insights when 10x Genomics shares its full-year 2024 financial guidance during the earnings call scheduled for the end of the month. This call will provide a platform for discussing not just third-quarter results, but also future expectations.
Webcast and Conference Call Details
The company invites interested parties to join the conference call to delve into its performance, developments, and outlook. This call will occur after market closure. Furthermore, a recorded version will be available for replay for those unable to attend live.
About 10x Genomics
10x Genomics is a pioneering life science technology firm committed to advancing biological understanding and improving human health. They offer integrated solutions that encompass instruments, consumables, and specialized software tailored for single cell and spatial biology. Their groundbreaking products have facilitated significant advancements across various fields including oncology and neuroscience.
Frequently Asked Questions
What were 10x Genomics' total revenues for Q3 2024?
The total revenue for Q3 2024 is expected to be approximately $151.7 million, representing a 1% decrease from the previous year.
How did 10x Genomics perform financially in different regions?
In the Americas, revenue dropped by 11%, while EMEA and APAC regions saw increases of 18% and 15%, respectively.
What challenges are impacting 10x Genomics' revenue?
Challenges include a cautious spending approach from customers, particularly regarding capital purchases and ongoing adjustments to commercial strategies.
When will 10x Genomics disclose its full-year 2024 guidance?
The full-year guidance will be shared during the earnings call on October 29, 2024.
How can I access the webcast of the earnings call?
The webcast of the earnings call will be available on the company's investor relations website, offering a detailed look into their performance and strategic direction.
